Gritstone Oncology (NASDAQ:GRTS) and Pluristem Therapeutics (NASDAQ:PSTI) Critical Survey

Gritstone Oncology (NASDAQ:GRTS) and Pluristem Therapeutics (NASDAQ:PSTI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership and profitability.

Analyst Ratings

This is a summary of recent ratings for Gritstone Oncology and Pluristem Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gritstone Oncology 0 1 6 0 2.86
Pluristem Therapeutics 0 0 3 0 3.00

Gritstone Oncology presently has a consensus target price of $22.20, indicating a potential upside of 126.07%. Pluristem Therapeutics has a consensus target price of $3.83, indicating a potential upside of 552.82%. Given Pluristem Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Pluristem Therapeutics is more favorable than Gritstone Oncology.

Institutional & Insider Ownership

48.8% of Gritstone Oncology shares are owned by institutional investors. Comparatively, 6.0% of Pluristem Therapeutics shares are owned by institutional investors. 38.0% of Gritstone Oncology shares are owned by insiders. Comparatively, 6.7% of Pluristem Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Gritstone Oncology and Pluristem Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Gritstone Oncology N/A N/A N/A
Pluristem Therapeutics N/A -197.88% -129.44%

Earnings and Valuation

This table compares Gritstone Oncology and Pluristem Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Gritstone Oncology $1.19 million 294.76 -$64.78 million ($7.26) -1.35
Pluristem Therapeutics $50,000.00 1,707.34 -$26.12 million ($0.25) -2.35

Pluristem Therapeutics has lower revenue, but higher earnings than Gritstone Oncology. Pluristem Therapeutics is trading at a lower price-to-earnings ratio than Gritstone Oncology, indicating that it is currently the more affordable of the two stocks.

Summary

Gritstone Oncology beats Pluristem Therapeutics on 7 of the 12 factors compared between the two stocks.

About Gritstone Oncology

Gritstone Oncology Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. Gritstone Oncology Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.

About Pluristem Therapeutics

Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies; a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has a collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.

Receive News & Ratings for Gritstone Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone Oncology and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit